3-aminophenanthreno<9,10-e>-1,2,4-triazine | 74246-63-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: 3-aminophenanthreno<9,10-e>-1,2,4-triazine
• 英文别名: 3-aminophenanthro<9,10-e>-1,2,4-triazine；phenanthro[9,10-e][1,2,4]triazin-3-amine；phenanthro[9,10-e][1,2,4]triazin-3-ylamine；Phenanthro[9,10-e][1,2,4]triazin-3-ylamin；3-Amino-phenanthreno<9',10':5,6>triazin
• CAS: 74246-63-2
• 化学式: C₁₅H₁₀N₄
• 分子量: 246.271
• InChiKey: RRBPZBNIQKRFIZ-UHFFFAOYSA-N

物化性质

• 沸点：
  561.7±33.0 °C(Predicted)
• 密度：
  1.417±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-溴环己酮 、 3-aminophenanthreno<9,10-e>-1,2,4-triazine 以 甲苯 为溶剂， 反应 2.0h， 以75%的产率得到tetrahydrobenzimidazo<1,2-b>phenanthreno<9,10-e>-1,2,4-triazine
  参考文献：
  名称：

  Povstyanoi, M. V.; Kruglenko, V. P.; Gnidets, V. P., Journal of Organic Chemistry USSR (English Translation), 1984, vol. 20, p. 1223 - 1224

  摘要：

  DOI：
• 作为产物：
  描述：

  3-Chloro-phenanthreno<9,10-e>-1,2,4-triazine 在 potassium amide 作用下， 以 氨 为溶剂， 反应 0.5h， 以85%的产率得到3-aminophenanthreno<9,10-e>-1,2,4-triazine
  参考文献：
  名称：

  Rykowski, Andrzej; Plas, Henk C. van der, Journal of Heterocyclic Chemistry, 1984, vol. 21, p. 433 - 434

  摘要：

  DOI：

文献信息

• [EN] CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS<br/>[FR] BLOQUEUR DE CANAUX SODIQUES TRIAZOÏQUES ET DIAZOÏQUES CYCLIQUES
  申请人：UNIV GREENWICH

  公开号：WO2009090431A1

  公开（公告）日：2009-07-23

  Compounds of general structure in which X and Y are each N or C with at least one of X and Y being N; Z is a single bond or an optionally substituted linking group R1 is hydrogen or a substituent group; R2 is amino or a substituent group; N* is amino when RI is hydrogen or =NH when R1 is a substituent group; or N* is a group NRaRb where Ra and Rb are independently H or an alkyl group; or N* is an optionally substituted piperazinyl ring; and A is an optionally substituted heterocyclic or carbocyclic ring system which may be linked to the triazo/diazo ring through R2 to form a fused multicyclic ring; are indicated as suitable for treatment of disorders in mammals that are susceptible to sodium channel blockers and antifolates, and particularly disorders such epilepsy, multiple sclerosis, glaucoma and uevitis, cerebral traumas and cerebral ischaemias, stroke, head injury, spinal cord injury, surgical trauma, neurodegenerative disorders, motorneurone disease, Alzheimer's disease, Parkinson's disease, chronic inflammatory pain, neuropathic pain, migraine, bipolar disorder, mood, anxiety and cognitive disorders, schizophrenia and trigeminal autonomic cephalalgias; for treatment of mammalian cancers; and for treatment of malaria.

  通用结构化合物，其中X和Y分别为N或C，至少X和Y中的一个为N；Z是单键或可选择性取代的连接基团；R1是氢或取代基团；R2是氨基或取代基团；N*是氨基，当R1为氢或=NH时，当R1为取代基团时；或N*是一个NRaRb基团，其中Ra和Rb分别为H或烷基基团；或N*是一个可选择性取代的哌嗪环；A是一个可选择性取代的杂环或碳环系统，可以通过R2与三唑/重氮环连接形成融合的多环环；适用于治疗对钠通道阻滞剂和抗叶酸类药物敏感的哺乳动物的疾病，特别是癫痫、多发性硬化、青光眼和葡萄膜炎、脑外伤和脑缺血、中风、头部损伤、脊髓损伤、手术创伤、神经退行性疾病、运动神经元疾病、阿尔茨海默病、帕金森病、慢性炎症性疼痛、神经病性疼痛、偏头痛、双相情感障碍、情绪、焦虑和认知障碍、精神分裂症和三叉神经自主性头痛；用于治疗哺乳动物癌症；以及用于治疗疟疾。
• CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS
  申请人：University of Greenwich

  公开号：US20140155403A1

  公开（公告）日：2014-06-05

  A method of treating a disorder. The method includes administering to a subject in need thereof a compound of formula (I): Each of A, N*, X, Y, Z, R1, and R2 is defined herein. Also disclosed are compounds of the formula and a pharmaceutical composition containing such a compound.

  一种治疗疾病的方法。该方法包括向需要治疗的受试者施用式（I）的化合物：其中A、N*、X、Y、Z、R1和R2均在此定义。还公开了该式的化合物和包含该化合物的制药组合物。
• Thiele; Bihan, Justus Liebigs Annalen der Chemie, 1898, vol. 302, p. 307
  作者：Thiele、Bihan

  DOI：——

  日期：——
• Rossi; Trave, Chimica e l'Industria (Milan, Italy), 1958, vol. 40, p. 827,829
  作者：Rossi、Trave

  DOI：——

  日期：——
• Synthesis, Three-Dimensional Structure, Conformation and Correct Chemical Shift Assignment Determination of Pharmaceutical Molecules by NMR and Molecular Modeling
  作者：Sirlene de Azeredo、Edijane Sales、José Figueroa-Villar

  DOI：10.21577/0103-5053.20160248

  日期：——

  This work includes the synthesis of phenanthrenequinone guanylhydrazone and phenanthro[9,10-e][1,2,4]triazin-3-amine to be tested as intercalate with DNA for treatment of cancer. The other synthesized product, 2-[(4-chlorophenylamino) methylene] malononitrile, was designed for future determination of its activity against leishmaniasis. A common problem about some articles on the literature is that some previously published compounds display error of their molecular structures. In this article it is shown the application of several procedures of nuclear magnetic resonance (NMR) to determine the complete molecular structure and the non questionable chemical shift assignment of the synthesized compounds, and also their analysis by molecular modeling to confirm the NMR results. To determine the capacity of pharmacological compounds to interact with biological targets is determined by docking. This work is to motivate the application of NMR and molecular modeling on organic synthesis, being a process that is very important for the study of the prepared compounds as interactions with biological targets by NMR.